Subtype	Biology	IO_Sensitivity	Key_Vulnerabilities	Primary_Drugs	Metabolic_Targets
SCLC-A (ASCL1-high)	Classical neuroendocrine, high DLL3, MYC-driven proliferation	Low - poor immune infiltration	DLL3 surface expression → Rovalpituzumab tesirine (Rova-T); BCL2 overexpression → BCL2 inhibitors (venetoclax); Aurora kinase dependency → AURKA inhibitors (alisertib)	Rovalpituzumab tesirine, Alisertib, Venetoclax	OXPHOS, Glutaminolysis
SCLC-N (NEUROD1-high)	Neuroendocrine variant, MYCN amplification, neural differentiation	Low - neuroendocrine phenotype	MYCN amplification → Aurora kinase inhibitors; MYC/MYCN dependency → BET inhibitors (JQ1); IGF1R signaling → IGF1R inhibitors	Alisertib, Olaparib, Volasertib	OXPHOS, Lipid synthesis
SCLC-P (POU2F3-high)	Tuft cell-like, non-neuroendocrine, chemoresistant	Moderate - variable immune infiltration	IGF1R overexpression → IGF1R inhibitors; FGFR1 amplification → FGFR inhibitors (erdafitinib); Notch pathway active → Notch inhibitors	Erdafitinib, Linsitinib, Nirogacestat	Glycolysis, One-carbon metabolism
SCLC-I (Inflamed)	Low neuroendocrine, high immune infiltration, T-cell inflamed	High - best IO responders	High PD-L1/PD-L2 → Immune checkpoint inhibitors; T-cell infiltration → Enhance with anti-CTLA4; IFN-γ signature → Biomarker for IO response	Atezolizumab, Durvalumab, Ipilimumab	IDO1, Tryptophan metabolism
